Bristol-Myers Squibb

Clinical Trial Results US Drug Label: ABILIFY®

Therapeutic Area	Indication	Study Ids	Title	Phase	Result Details
Psychiatric Disorders	Autism	CN138-178 ST	A Multicenter Double-Blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder	III	Result
Psychiatric Disorders	Bipolar Disorder	CN138-008 ST	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF ARIPIPRAZOLE AND HALOPERIDOL IN THE MAINTAINED RESPONSE TO TREATMENT FOR AN ACUTE MANIC EPISODE	III	Publica- tion Reference /Result
Psychiatric Disorders	Clinical Pharmacology	CN138-022	SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ARIPIPRAZOLE AND CARBAMAZEPINE COADMINISTRATION IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER	I	Result
Psychiatric Disorders	Dementia	CN138-131	A Double-Blind Placebo Controlled Pilot Tolerability Study of Intramuscular Aripiprazole in the Treatment of Acutely Agitated Patient's with a Diagnosis of Alzheimer's, Vascular or Mixed Dementia	II	Publica- tion Reference /Result
Psychiatric Disorders	Depression	CN138-165 ST	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Aripiprazole as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder	III	Result
Psychiatric Disorders	Mania	CN138-013	A Randomized, Double-Blind Comparison of the Efficacy and Safety of Aripiprazole Intramuscular Formula, Lorazepam or Placebo in the Treatment of Acutely Agitated Patients Diagnosed with Bipolar I Disorder, Manic or Mixed	III	Publica- tion Reference
Psychiatric Disorders	Mixed Anxiety Depression	CN138-177	Effects of Aripiprazole on the Steady-State Pharmacokinetics of Escitalopram or Venlaxfaxine in Depressive or Anxiety-Disorder Subjects	I	Result
Psychiatric Disorders	Psychosis	CN138-060	A Pilot Open-Label, Flexible Dose Study to Evaluate the Safety and Tolerability of Aripiprazole in Patients with Phychosis Associated with Parkinson's Disease	II	Result
Psychiatric Disorders	Psychosis	CN138-004	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study of Three Fixed Doses of Aripiprazole in the Treatment of Institutionalized Patients with Psychosis Associated with Dementia of the Alzheimer's Type	III	Publica- tion Reference /Result
Psychiatric Disorders	Psychosis	CN138-004 LT	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study of Three Fixed Doses of Aripiprazole in the Treatment of Institutionalized Patients with Psychosis Associated with Dementia of the Alzheimer's Type	III	Publica- tion Reference /Result
Psychiatric Disorders	Psychosis	CN138-005	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study of Aripiprazole in the Treatment of Institutionalized Patients with Psychosis Associated with Dementia of the Alzheimer's Type	III	Publica- tion Reference /Result
Psychiatric Disorders	Psychosis	CN138-005 LT	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study of Aripiprazole in the Treatment of Institutionalized Patients with Psychosis Associated with Dementia of the Alzheimer's Type	III	Publica- tion Reference /Result
Psychiatric Disorders	Psychosis	CN138-006	A MULITCENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, FLEXIBLE DOSE STUDY OF ARIPIPRAZOLE IN THE TREATMENT OF PATIENTS WITH PSYCHOSIS ASSOCIATED WITH DEMENTIA OF ALZHEIMER'S TYPE	III	Publica- tion Reference /Result
Psychiatric Disorders	Psychotic Disorders	CN138-122	A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole on Overweight Pateints Treated with Olanzapine for Schizophrenia or Schizoaffective Disorder	III	Publica- tion Reference /Result
Psychiatric Disorders	Schizophrenia	CN138-152	A Multicenter, Randomized, Naturalistic, Open-Label Study between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole: the STAR Study)	III	Publica- tion Reference /Result
Psychiatric Disorders	Schizophrenia	CN138-125	A prospective multicenter, Open-Label Study of Aripiprazole in the Management of Patients with Schizophrenia in General Psychiatric Practices	IV	Result
Psychiatric Disorders	Schizophrenia	CN138-166	A prospective, Multicenter,OL Study to evaluate the Effectiveness and the effect on Cognitive Functioning of a Ttmt with Aripiprazole when the product is administered to in a Broad Range of Schizophrenic Patients.	IV	Result
Psychiatric Disorders	Schizophrenia	CN138-397 ST	A Multicenter, Randomized, Double-blind, Placebo-controlled, 16-Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients with Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy	IV	Result
Psychiatric Disorders	Schizophrenia, Acute Exacerbation	CN138-003 ST	A Multicenter, Double-Blind, Randomized Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients with Acute Schizophrenia	III	Result
Psychiatric Disorders	Schizophrenia, Acute Exacerbation	CN138-113	A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Three Fixed Doses of Aripiprazole in the Treatment of Patients with Acute Schizophrenia	IV	Publica- tion Reference /Result
Psychiatric Disorders	Schizophrenia, Acute Exacerbation	CN138-169 ST	A Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are Experiencing Insufficient Efficacy with Risperidone and/or Safety and Tolerability Issues While on Risperidone.	IV	Result
Psychiatric Disorders	Schizophrenia, Acute Exacerbation	CN138-170 LT	A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment with Aripiprazole in Patients with Schizophrenia	IV	Result
Psychiatric Disorders	Schizophrenia, Acute Exacerbation	CN138-170 ST	A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment with Aripiprazole in Patients with Schizophrenia	IV	Result